What is the clinical evidence from this study?

Study design: RCT. Population: Non-ST segment elevation acute coronary syndrome (NSTE-ACS) (n=10074). Intervention: Prasugrel vs. Clopidogrel. Primary outcome: Primary ischaemic endpoint (HR 0.82, 95% CI 0.73-0.93, p=0.002).

What does this research mean for the field?

Prasugrel significantly reduces ischemic events compared with clopidogrel in patients with non-ST-elevation acute coronary syndromes, conferring an overall net clinical benefit despite an increased risk of major bleeding. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the efficacy and safety of prasugrel compared with clopidogrel in patients presenting with non-ST-segment elevation acute coronary syndrome.

May 12, 2014European Heart Journal Acute Cardiovascular Care

Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial

Q: What are the key findings of this study?

Prasugrel significantly reduced the primary ischaemic endpoint compared with clopidogrel in patients with NSTE-ACS (HR 0.82; 95% CI 0.73-0.93; p=0.002), though major bleeding was increased.

View Full Paper

Ask AI

Bookmark

Key result

Prasugrel reduces ischaemic events ~18% vs. clopidogrel in NSTE-ACS, though major bleeding increases.

HR 0.82
95% CI 0.73-0.93
P=0.002
n=10,074

Why the study?

Prasugrel reduced ischemic events but increased bleeding compared with clopidogrel in ACS patients undergoing PCI, requiring detailed analysis in NSTE-ACS subgroups.

Population

10,074 NSTE-ACS patients including unstable angina and NSTEMI

Comparison

Prasugrel versus clopidogrel

Design

Randomized controlled trial (TRITON-TIMI 38)

Follow-up

365 days

Authors

SSStefano De ServiInterventional Cardiology JGJochen GoedickeEli Lilly (Germany)ASAndreas SchirmerMorphoSys (Germany)

Discussion

Member takes

Implication

Supports prasugrel over clopidogrel in NSTE-ACS despite bleeding increase; confirms ischaemic benefit of potent P2Y12 inhibition in this population.

Key Points

To evaluate the efficacy and safety of prasugrel compared with clopidogrel in patients presenting with non-ST-segment elevation acute coronary syndrome.
Subgroup analysis of 10,074 patients with non-ST-elevation acute coronary syndrome (unstable angina or NSTEMI) scheduled for percutaneous coronary intervention in the randomized TRITON-TIMI 38 trial.
Outcomes assessed included the primary ischemic endpoint, non-CABG TIMI major bleeding, net clinical benefit, and specific evaluation of the European Union-label cohort (excluding patients with prior TIA/stroke, weight <60 kg, or age ≥75 years, censored at 365 days).
Prasugrel significantly reduced the primary ischemic endpoint in the overall NSTE-ACS population (HR 0.82, 95% CI 0.73–0.93, p=0.002) and demonstrated overall net clinical benefit (HR 0.89, 95% CI 0.80–1.00, p=0.043), despite increasing non-CABG TIMI major bleeding (HR 1.40, 95% CI 1.05–1.88, p=0.02).
In the European Union-label cohort, prasugrel demonstrated superiority over clopidogrel for the primary endpoint (HR 0.73, 95% CI 0.63–0.85, p<0.0001) without a statistically significant difference in non-CABG TIMI major bleeding.

Study Design

Type

RCT (n=10,074)

PICO

Population

10,074 patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) planned to undergo percutaneous coronary interventions.

Intervention / Comparator

Prasugrel vs Clopidogrel

Primary Outcome

Primary ischaemic endpoint — HR 0.82 (0.73-0.93), p=0.002

Main Result

Hazard Ratio: 0.82 (95% CI 0.73–0.93)

p-value: p=0.002

Cite This Study

Servi et al. (2014) conducted an RCT in Non-ST segment elevation acute coronary syndrome (NSTE-ACS) (n=10,074). Prasugrel vs. Clopidogrel was evaluated on Primary ischaemic endpoint (HR 0.82, 95% CI 0.73-0.93, p=0.002). Prasugrel significantly reduced the primary ischaemic endpoint compared with clopidogrel in patients with NSTE-ACS (HR 0.82; 95% CI 0.73-0.93; p=0.002), though major bleeding was increased.

synapsesocial.com/papers/6ab340fb8b8e5c755345c351 https://doi.org/10.1177/2048872614534078

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Implication

Supports prasugrel over clopidogrel in NSTE-ACS despite bleeding increase; confirms ischaemic benefit of potent P2Y12 inhibition in this population.

Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial

Discussion

Member takes

Implication

Key Points

Study Design

PICO

Main Result

Cite This Study

Topics

Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial

Discussion

Member takes

Implication

Key Points

Study Design

PICO

Main Result

Cite This Study

Also Consider

Topics

Also Consider